About Janux Therapeutics
Janux Therapeutics is a company based in San Diego (United States) founded in 2017 by David Campbell.. Janux Therapeutics has raised $181 million across 2 funding rounds from investors including Citadel, Orbimed and Janus Henderson Investors. The company has 81 employees as of December 31, 2024. Janux Therapeutics offers products and services including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008). Janux Therapeutics operates in a competitive market with competitors including Sana Biotechnology, GigaGen, Kronos Bio, Carisma Therapeutics and Asher Biotherapeutics, among others.
- Headquarter San Diego, United States
- Employees 81 as on 31 Dec, 2024
- Founders David Campbell
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Janux Therapeutics, Inc.
-
Annual Revenue
$10.59 M30.99as on Dec 31, 2024
-
Net Profit
$-68.99 M-18.36as on Dec 31, 2024
-
EBITDA
$-96.79 M-36.27as on Dec 31, 2024
-
Total Equity Funding
$181 M (USD)
in 2 rounds
-
Latest Funding Round
$125 M (USD), Series B
Apr 20, 2021
-
Investors
Citadel
& 10 more
-
Employee Count
81
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Janux Therapeutics
Janux Therapeutics is a publicly listed company on the NASDAQ with ticker symbol JANX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Janux Therapeutics
Janux Therapeutics offers a comprehensive portfolio of products and services, including PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tumor-activated T cell engager targeting prostate cancer
Tumor-activated T cell engager for EGFR-related cancers
Unlock access to complete
Unlock access to complete
Leadership Team
21 people
Senior Team
12 people
Finance and Accounting
8 people
Operations Team
5 people
Advisor Team
5 people
Product Management Team
5 people
Software Development Team
3 people
Scientist Team
3 people
Unlock access to complete
Funding Insights of Janux Therapeutics
Janux Therapeutics has successfully raised a total of $181M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $125 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $125.0M
-
First Round
First Round
(03 Mar 2021)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Series B - Janux Therapeutics | Valuation | RA Capital Management | |
| Mar, 2021 | Amount | Series A - Janux Therapeutics | Valuation | Avalon Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Janux Therapeutics
Janux Therapeutics has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Citadel, Orbimed and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US private equity investments are managed by BVF Partners.
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Janux Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Janux Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Janux Therapeutics Comparisons
Competitors of Janux Therapeutics
Janux Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, GigaGen, Kronos Bio, Carisma Therapeutics and Asher Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Chimeric antigen receptor macrophages are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of cancer and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Janux Therapeutics
Frequently Asked Questions about Janux Therapeutics
When was Janux Therapeutics founded?
Janux Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is Janux Therapeutics located?
Janux Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Janux Therapeutics?
David Campbell is the current CEO of Janux Therapeutics. They have also founded this company.
Is Janux Therapeutics a funded company?
Janux Therapeutics is a funded company, having raised a total of $181M across 2 funding rounds to date. The company's 1st funding round was a Series A of $56M, raised on Mar 03, 2021.
How many employees does Janux Therapeutics have?
As of Dec 31, 2024, the latest employee count at Janux Therapeutics is 81.
What is the annual revenue of Janux Therapeutics?
Annual revenue of Janux Therapeutics is $10.59M as on Dec 31, 2024.
What does Janux Therapeutics do?
Janux Therapeutics was founded in 2017 and is headquartered in San Diego, United States. Focus is placed on the biotechnology sector, specifically oncology, where immunotherapeutics are developed for solid tumors such as colorectal, gastroesophageal, prostate, NSCLC, triple-negative breast, and ovarian cancers. Lead candidates include TROP2-TRACTr, PSMA-TRACTr, EGFR-TRACTr, HER2-TRACTr, and costim bispecifics. T cell engagers that bind tumor cells and activate patient T-cells for tumor eradication are also being advanced.
Who are the top competitors of Janux Therapeutics?
Janux Therapeutics's top competitors include Kronos Bio, Sana Biotechnology and GigaGen.
What products or services does Janux Therapeutics offer?
Janux Therapeutics offers PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008).
Is Janux Therapeutics publicly traded?
Yes, Janux Therapeutics is publicly traded on NASDAQ under the ticker symbol JANX.
Who are Janux Therapeutics's investors?
Janux Therapeutics has 11 investors. Key investors include Citadel, Orbimed, Janus Henderson Investors, RA Capital, and Hartford Hospital.
What is Janux Therapeutics's ticker symbol?
The ticker symbol of Janux Therapeutics is JANX on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.